Cutaneous Squamous Cell Carcinoma (cSCC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in cSCC therapeutics.
More than 16 million diagnosed prevalent cases of DN are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for DN.
Among the marketed DN drugs available, most of the drugs are enzyme inhibitors, followed by receptor antagonists, by mechanism of action.
The DN pipeline consists of over 95 drugs spanning all stages of development (discovery to late-stage clinical development), with only 4.2% of drugs present in Phase III.
Of the 441 trials initiated in DN the past 10 years, 286 trials have been completed, while 100 trials are currently ongoing.
Partnerships were the most prominent type of deal ventured in the DN space globally.
Scope
GlobalData’s cSCC: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the cSCC market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cSCC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Disease etiology
Epidemiology Overview
Epidemiology Overview - Diagnosed Incident Cases of First-Ever cSCC in 2023 and 2028
Treatment Overview
Treatment Guidelines
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in cSCC
Marketed Drug Profile - Merck & Co.' s Keytruda
Marketed Drug Profile - Sanofi/Regeneron's Libtayo
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy
Marketed Drugs - Time to Pricing and Reimbursement for Keytruda
Marketed Drugs - Time to Pricing and Reimbursement for Libtayo
Pipeline Drugs Assessment
Pipeline Drugs Overview - Pipeline Drugs in cSCC
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - PTSR and LoA in Oncology and SCC
Clinical Trials Assessment
Clinical Trials in cSCC - Historical Overview
Clinical Trials in cSCC - Overview by Phase
Clinical Trials in cSCC - Overview by Status
Clinical Trials in cSCC - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in cSCC - Geographic Overview
Clinical Trials in cSCC - Single-Country and Multinational Trials by Region
Clinical Trials in cSCC - Top Sponsors with Breakdown by Phase
Clinical Trials in cSCC - Top Sponsors with Breakdown by Status
Clinical Trials in cSCC - Overview by Endpoint Status
Clinical Trials in cSCC - Overview by Race and Ethnicity
Clinical Trials in cSCC - Enrollment Data
Table Enrollment data for Phase II trials in cSCC
Clinical Trials in cSCC - Overview of Sites by Geography
Clinical Trials in cSCC - Top 20 Countries for Trial Sites
Clinical Trials in cSCC - Top 20 Sites Globally
Clinical Trials - Feasibility Analysis for Adenoid SCC: Geography Overview
Clinical Trials - Feasibility Analysis: Benchmark Models for Adenoid SCC
Clinical Trials - Feasibility Analysis: Benchmark Models for Phase II Spindle Cell SCC and Keratoacanthoma
Deals Landscape
Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in cSCC by Region
Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in cSCC
Commercial Assessment
Commercial Assessment - Key Market Players in cSCC
Future Market Catalysts
Future Market Catalysts - Upcoming Market Catalysts in cSCC
Appendix
Methodology
Methodology - Sales Forecasts
Methodology - Pricing and Reimbursement
Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis